Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2025. The document serves as a transaction notification reporting share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The transactions occurred on October 9, 2025 (London Stock Exchange) and October 10, 2025 (New York Stock Exchange).
Key Financial Metrics and Transaction Details
The filing details the acquisition of shares via dividend reinvestment plans. No corporate financial metrics (revenue, profit, cash flow) are provided in this specific transaction report.
| Instrument | Transaction Date | Exchange | Price | Total Volume (Shares/ADS) |
|---|---|---|---|---|
| Ordinary Shares (GBP) | 2025-10-09 | London Stock Exchange | £16.3921 - £16.4016 | ~23,000 (Aggregated) |
| American Depositary Shares (USD) | 2025-10-10 | New York Stock Exchange | $43.7375 | 582 |
Notable Individual Acquisitions (Ordinary Shares):
- David Redfern (President, Corporate Development): 6,278.135 shares
- Regis Simard (President, Global Supply Chain): 2,616.351 shares
- Philip Thomson (President, Global Affairs): 2,144.723 shares
- Diana Conrad (Chief People Officer): 1,233.149 shares
- Iain Whyte (PCA of Victoria Whyte): 1,152 shares
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy. It strictly documents routine share acquisitions resulting from the reinvestment of dividends paid on October 9, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The nature of the transaction is purely administrative, reflecting participation in the Company's Share Reward Plan.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs against the company's latest insider trading reports to ensure compliance with trading windows.
- Confirm the dividend reinvestment price (£16.3921/£16.4016 and $43.7375) aligns with the market price on the transaction dates.
- Note that these transactions represent acquisitions (buying), not sales, indicating no immediate insider selling pressure.
- Review the company's annual report (Form 20-F) for broader financial performance, as this 6-K contains no revenue or earnings data.